HRP20171213T1 - Glikoproteinske čestice nalik virusu (vlp) bjesnoće - Google Patents
Glikoproteinske čestice nalik virusu (vlp) bjesnoće Download PDFInfo
- Publication number
- HRP20171213T1 HRP20171213T1 HRP20171213TT HRP20171213T HRP20171213T1 HR P20171213 T1 HRP20171213 T1 HR P20171213T1 HR P20171213T T HRP20171213T T HR P20171213TT HR P20171213 T HRP20171213 T HR P20171213T HR P20171213 T1 HRP20171213 T1 HR P20171213T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- rabies virus
- micelles
- antibodies against
- host
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title claims 3
- 108090000288 Glycoproteins Proteins 0.000 title claims 3
- 206010037742 Rabies Diseases 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 14
- 241000711798 Rabies lyssavirus Species 0.000 claims 12
- 108091006027 G proteins Proteins 0.000 claims 10
- 102000030782 GTP binding Human genes 0.000 claims 10
- 108091000058 GTP-Binding Proteins 0.000 claims 10
- 239000000693 micelle Substances 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000282421 Canidae Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000288673 Chiroptera Species 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241000266847 Mephitidae Species 0.000 claims 1
- 241000282335 Procyon Species 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (13)
1. Postupak za izradu micela, koje sadrđe glikoproteine (G proteine) virusa bjesnoće (RV), naznačen time da G proteini tvore trimer koji sadrži:
(a) Transformiranje Sf9 stanice domaćina kukca s jednim bakulovirusnim vektorom, koji obuhvaća jednu nukleinsku kiselinu, koja kodira jedan G protein od virusa bjesnila (RV);
(b) Uzgoj navedene stanice domaćina za ekspresiju nukleinsku kiselinu; i
(c) Pročišćavanje G proteina od virusa bjesnila (RV) u obliku micela.
2. Postupak sukladno patentnom zahtjevu 1, naznačen time da je nukleinska kiselina kodon optimizirana za ekspresiju u navedenim stanicama domaćina.
3. Postupak sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time da G protein od virusa bjesnoće (RV) sadrži SEK ID BR:2.
4. Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da je G protein od virusa bjesnoće (RV) izveden iz jednog soja virusa bjesnoće, odabranog između čovjeka, pasa, šišmiša, rakuna, tvora i lisica.
5. Postupak za pripravu cjepiva ili antigenskog pripravka, koji obuhvaća izradu micela, koje sadrže glikoproteine iz virusa bjesnoće, pomoću postupka metodom prema bilo kojem od patentnih zahtjeva 1 do 4 te nadalje obuhvata korak formuliranja micela kao cjepiva ili antigenskog sastava, dodavanjem djelotvorne doze od micela do sastava.
6. Postupak sukladno patentnom zahtjevu 5, naznačen time što navedeni pripravak sadrži farmaceutski prihvatljiv nosač, razrjeđivač, ili ekscipijens.
7. Postupak sukladno patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačen time da pripravak sadrži adjuvant.
8. Postupak sukladno patentnom zahtjevu 7, naznačen time da je adjuvant jedan aluminijski adjuvans.
9. Postupak sukladno patentnom zahtjevu 1, da je micela sposobna povećati proizvodnju antitijela protiv G proteina u domaćinu.
10. Postupak sukladno patentnom zahtjevu 9, naznačen time da su navedena antitijela protiv G proteina zaštitna.
11. Postupak sukladno patentnom zahtjevu 9, naznačen time da su navedena antitijela protiv G proteina zaštitna.
12. Postupak sukladno patentnom zahtjevu 9, naznačen time da su micele sposobne inducirati proizvodnju antitela protiv G proteina u domaćinu, nakon davanja jedne doze.
13. Postupak sukladno patentnom zahtjevu 9, naznačen time da su micele podobne osigurati seroprotektivni titar unutar 7 dan
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41076710P | 2010-11-05 | 2010-11-05 | |
| EP11838942.8A EP2635257B1 (en) | 2010-11-05 | 2011-11-07 | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs) |
| PCT/US2011/059602 WO2012061815A2 (en) | 2010-11-05 | 2011-11-07 | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171213T1 true HRP20171213T1 (hr) | 2017-10-20 |
Family
ID=46025156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171213TT HRP20171213T1 (hr) | 2010-11-05 | 2017-08-08 | Glikoproteinske čestice nalik virusu (vlp) bjesnoće |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9724405B2 (hr) |
| EP (2) | EP2635257B1 (hr) |
| JP (2) | JP6158088B2 (hr) |
| KR (1) | KR101847908B1 (hr) |
| CN (2) | CN109157658A (hr) |
| AU (1) | AU2011323090B2 (hr) |
| BR (1) | BR112013011194B1 (hr) |
| CA (1) | CA2817005C (hr) |
| CY (1) | CY1119284T1 (hr) |
| DK (1) | DK2635257T3 (hr) |
| ES (1) | ES2636965T3 (hr) |
| HR (1) | HRP20171213T1 (hr) |
| HU (1) | HUE034247T2 (hr) |
| LT (1) | LT2635257T (hr) |
| MX (1) | MX354750B (hr) |
| PL (1) | PL2635257T3 (hr) |
| PT (1) | PT2635257T (hr) |
| RS (1) | RS56157B1 (hr) |
| SG (1) | SG190140A1 (hr) |
| SI (1) | SI2635257T1 (hr) |
| WO (1) | WO2012061815A2 (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| PT2610345E (pt) | 2007-11-27 | 2016-01-11 | Medicago Inc | Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| LT3067064T (lt) | 2008-12-09 | 2020-09-10 | Novavax, Inc. | Modifikuoti rsv f baltymai ir jų panaudojimo būdai |
| NO2480560T3 (hr) | 2009-09-22 | 2018-07-21 | ||
| CN109157658A (zh) * | 2010-11-05 | 2019-01-08 | 诺瓦瓦克斯股份有限公司 | 狂犬病糖蛋白病毒样颗粒(vlp) |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| WO2012171104A1 (en) * | 2011-06-13 | 2012-12-20 | Medicago Inc. | Rabies virus like particle production in plants |
| KR101479668B1 (ko) | 2012-07-31 | 2015-01-12 | 대한민국 | 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물 |
| CN103777021B (zh) * | 2012-10-18 | 2016-03-02 | 辽宁成大生物股份有限公司 | 狂犬疫苗糖蛋白含量的检测方法 |
| MX2018002728A (es) | 2015-09-03 | 2018-09-05 | Novavax Inc | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. |
| CN106905434B (zh) * | 2017-02-28 | 2021-01-26 | 国药中生生物技术研究院有限公司 | 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 |
| EP3420076B1 (en) * | 2017-03-06 | 2024-02-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| WO2018161858A1 (en) | 2017-03-06 | 2018-09-13 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| CN111315409A (zh) * | 2017-11-06 | 2020-06-19 | 英特维特国际股份有限公司 | 狂犬病毒疫苗 |
| CA3092984A1 (en) | 2018-03-19 | 2019-09-26 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
| KR102077772B1 (ko) | 2018-11-29 | 2020-02-17 | 주식회사 바이오앱 | 광견병 예방용 백신 조성물 및 이의 제조 방법 |
| KR102211077B1 (ko) * | 2019-01-16 | 2021-02-02 | 충남대학교 산학협력단 | 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신 |
| CN109959789B (zh) * | 2019-04-12 | 2022-08-16 | 长春西诺生物科技有限公司 | 一种狂犬病毒抗体检测试纸及其制备方法与检测方法 |
| CN110007080B (zh) * | 2019-04-12 | 2022-09-23 | 长春西诺生物科技有限公司 | 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法 |
| WO2023064931A1 (en) * | 2021-10-15 | 2023-04-20 | La Jolla Institute For Immunology | Engineered rabies virus glycoprotein, compositions, and methods of use thereof |
| CN114272367B (zh) * | 2021-12-03 | 2023-07-07 | 华东理工大学 | 一种口服狂犬病病毒样颗粒疫苗及其制备方法 |
| KR102566969B1 (ko) | 2021-12-14 | 2023-08-16 | 안희철 | 근거리 통신 과정에서 충전 가능한 모바일 단말 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0237686A1 (en) * | 1986-03-18 | 1987-09-23 | Institut Pasteur | DNA sequences derived from the rabies virus genome |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5667782A (en) * | 1992-07-16 | 1997-09-16 | Oxford University | Multiple particulate antigen delivery system |
| US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US6589533B1 (en) * | 1997-09-18 | 2003-07-08 | Research Development Foundation | Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
| US6673601B1 (en) | 1999-04-15 | 2004-01-06 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
| AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| WO2003047493A2 (en) * | 2001-12-03 | 2003-06-12 | Dor Biopharma Inc. | Stabilized reverse micelle compositions and uses thereof |
| US7211378B2 (en) | 2002-01-31 | 2007-05-01 | Wisconsin Alumni Research Foundation | Filovirus vectors and noninfectious filovirus-based particles |
| WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
| US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| CN101405389A (zh) | 2006-01-17 | 2009-04-08 | 生物载体株式会社 | 新型蛋白质表达系统 |
| US8153115B2 (en) | 2006-06-15 | 2012-04-10 | Ben-Gurion University Of The Negev Research And Development Authority | Virus-like particles for treatment of viral infections |
| WO2008005777A2 (en) * | 2006-06-30 | 2008-01-10 | Novavax, Inc. | Methods of enhancing protein incorporation into virus like particles |
| US8980281B2 (en) | 2006-09-05 | 2015-03-17 | Academia Sinica | High-yield transgenic mammalian expression system for generating virus-like particles |
| TW200907058A (en) | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| KR20100063030A (ko) * | 2007-07-19 | 2010-06-10 | 노바백스, 인코포레이티드 | 바리셀라 조스터 바이러스-바이러스 유사 입자(ＶＬＰｓ) 및 항원 |
| KR100961280B1 (ko) * | 2008-05-21 | 2010-06-03 | 한국생명공학연구원 | 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도 |
| WO2009153801A1 (en) | 2008-06-17 | 2009-12-23 | Manpreet Kaur | Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| LT3067064T (lt) * | 2008-12-09 | 2020-09-10 | Novavax, Inc. | Modifikuoti rsv f baltymai ir jų panaudojimo būdai |
| CN109157658A (zh) | 2010-11-05 | 2019-01-08 | 诺瓦瓦克斯股份有限公司 | 狂犬病糖蛋白病毒样颗粒(vlp) |
-
2011
- 2011-11-07 CN CN201810963479.7A patent/CN109157658A/zh active Pending
- 2011-11-07 KR KR1020137014262A patent/KR101847908B1/ko active IP Right Grant
- 2011-11-07 PL PL11838942T patent/PL2635257T3/pl unknown
- 2011-11-07 SI SI201131258T patent/SI2635257T1/en unknown
- 2011-11-07 BR BR112013011194-1A patent/BR112013011194B1/pt active IP Right Grant
- 2011-11-07 CN CN201180064287.9A patent/CN103282023B/zh active Active
- 2011-11-07 LT LTEP11838942.8T patent/LT2635257T/lt unknown
- 2011-11-07 DK DK11838942.8T patent/DK2635257T3/en active
- 2011-11-07 PT PT118389428T patent/PT2635257T/pt unknown
- 2011-11-07 ES ES11838942.8T patent/ES2636965T3/es active Active
- 2011-11-07 EP EP11838942.8A patent/EP2635257B1/en active Active
- 2011-11-07 JP JP2013537909A patent/JP6158088B2/ja active Active
- 2011-11-07 RS RS20170786A patent/RS56157B1/sr unknown
- 2011-11-07 EP EP17179212.0A patent/EP3246019B1/en active Active
- 2011-11-07 CA CA2817005A patent/CA2817005C/en active Active
- 2011-11-07 MX MX2013005090A patent/MX354750B/es active IP Right Grant
- 2011-11-07 US US13/883,745 patent/US9724405B2/en active Active
- 2011-11-07 HU HUE11838942A patent/HUE034247T2/en unknown
- 2011-11-07 WO PCT/US2011/059602 patent/WO2012061815A2/en active Application Filing
- 2011-11-07 AU AU2011323090A patent/AU2011323090B2/en active Active
- 2011-11-07 SG SG2013034178A patent/SG190140A1/en unknown
-
2016
- 2016-09-27 JP JP2016188777A patent/JP6195965B2/ja active Active
-
2017
- 2017-06-30 US US15/638,955 patent/US10086065B2/en active Active
- 2017-08-08 HR HRP20171213TT patent/HRP20171213T1/hr unknown
- 2017-08-11 CY CY20171100873T patent/CY1119284T1/el unknown
-
2018
- 2018-08-30 US US16/116,990 patent/US20190224307A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| Chen et al. | Advances in development and application of influenza vaccines | |
| JP2017035093A5 (hr) | ||
| Zhu et al. | Rabies control and treatment: from prophylaxis to strategies with curative potential | |
| Kim et al. | Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus | |
| Kim et al. | Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection | |
| JP2014500013A5 (hr) | ||
| JP2022066209A (ja) | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス | |
| JP2013216685A5 (hr) | ||
| Wang et al. | Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases | |
| Astray et al. | Rabies vaccine development by expression of recombinant viral glycoprotein | |
| US11389523B2 (en) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein | |
| Zhang et al. | Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice | |
| Krammer et al. | Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis | |
| CA3010977A1 (en) | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus | |
| Quan et al. | Progress in the development of virus-like particle vaccines against respiratory viruses | |
| Du et al. | Flu universal vaccines: new tricks on an old virus | |
| JP2022551805A (ja) | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス | |
| Chu et al. | Virus-like particle vaccines against respiratory viruses and protozoan parasites | |
| Wohlbold et al. | An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13 | |
| Tian et al. | A rabies virus vectored severe fever with thrombocytopenia syndrome (SFTS) bivalent candidate vaccine confers protective immune responses in mice | |
| CN108348596B (zh) | 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 | |
| Szurgot et al. | Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform | |
| Hernandez et al. | Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs |